These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 24120891)
1. Innovators working hard to avoid patent exclusions in the US. Tombling A Drug Discov Today; 2013 Dec; 18(23-24):1131-2. PubMed ID: 24120891 [No Abstract] [Full Text] [Related]
8. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech. Garber K Science; 2006 May; 312(5775):827. PubMed ID: 16690824 [No Abstract] [Full Text] [Related]
9. Patent watch: Progress in three key patent disputes in 2009. Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395 [No Abstract] [Full Text] [Related]
10. The ITC as an attractive patent litigation forum for the biotechnology and pharmaceutical industry. Burton CA; Margonis LE Pharm Pat Anal; 2013 Mar; 2(2):177-80. PubMed ID: 24237023 [No Abstract] [Full Text] [Related]
12. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
13. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1). Tsao R; Hurley EA Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112 [No Abstract] [Full Text] [Related]
16. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
17. Robert Stoll. Interview by Charlotte Harrison. Stoll R Nat Rev Drug Discov; 2009 Dec; 8(12):926. PubMed ID: 19949397 [No Abstract] [Full Text] [Related]
18. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]